mergers & acquisitions

Sygnis said that TGR is profitable and has a complementary product portfolio that includes protein capture technology.

Thermo Fisher said that IntegenX complements and enhances its existing human identification product portfolio.

Near-term the deal gives Quanterix a CLIA lab while securing technologies that could improve assay multiplexing and support its longer term clinical goals.

IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.

Advanced Analytical markets CE instruments, reagents, and software for nucleic acid analysis while Lasergen is a next-generation sequencing technology developer.

Through the deal, BioDuro has acquired Molecular Response's translational oncology research platform and its biobank of viable tumor specimens.

Genoptix's $9 million bid for Rosetta comes just days after the companies' first merger agreement failed to secure shareholder approval.

The company said PerkinElmer will pay A$.28 per share for its 89.9 million outstanding shares, a 100 percent premium to RHS's Feb. 23 closing price on the ASX.

Genoptix terminated the merger agreement after an insufficient number of Rosetta shareholders voted in favor of the deal.

LGC Acquires Lucigen

London-based LGC said that the acquisition increases its exposure to the next-generation sequencing and gene editing markets.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.